Farmas USA

...reporting directly to Patrick J.
McEnany, Catalyst’s Chairman and CEO. Mr. Ailinger will be responsible for
leading the Company’s business development and corporate strategy
initiatives, including licensing and partnering discussions.


We are delighted to add David to our senior management team at such a
transformative time for our Company,” said Mr. McEnany. “Dave is a
seasoned veteran with 15 years of business development experience with branded
drugs. He brings valuable new skills to Catalyst at a time when business
development is a core strategic focus for us, as we look to broaden our
portfolio of commercial products, our pipeline of late-stage development
programs, and our global footprint.”

“I am excited to join Catalyst as the Company continues to make an impact
for those suffering from rare diseases,” said David Ailinger. “I look
forward to working with the Catalyst team as we seek to grow our business and
bring innovative therapies to patients worldwide.”

Mr. Ailinger most recently served as Senior Director of Corporate Development
at Impax Laboratories, where he was responsible for business development
activities for specialty products, including the identification, evaluation,
negotiation and execution of business development activities. Prior to joining
Impax, Mr. Ailinger was Executive Director of global business development at
Actavis (formerly Watson Pharmaceuticals). At Actavis, he was responsible for
leading global brand business development initiatives. Prior to joining
Actavis, Mr. Ailinger was a director of business development and licensing at
Teva Pharmaceuticals, previously Barr Laboratories, where he performed a
series of roles in corporate and business development across multiple
therapeutic areas.